GyneCure
GyneCure Brand names, GyneCure Analogs
- Fungibacid
- GyneCure
- GyneCure Ovules
- GyneCure Vaginal Ointment Tandempak
- GyneCure Vaginal Ovules Tandempak
- Gyno-trosyd
- Monistat 1
- Oxiconazolc Nitrate
- Oxiconazole
- Oxiconazole nitrate
- Thioconazole
- Tioconazol [INN-Spanish]
- Tioconazole [USAN:BAN:INN:JAN]
- Tioconazolum [INN-Latin]
- Trosyd
- Trosyd AF
- Trosyd J
- Trosyl
- Tz-3
- Vagistat
- Vagistat-1
- Zoniden
GyneCure Brand Names Mixture
- No information avaliable
GyneCure Chemical_Formula
C8H15NO2
GyneCure RX_link
http://www.rxlist.com/cgi/generic3/cyclapron.htm
GyneCure fda sheet
GyneCure msds (material safety sheet)
GyneCure Synthesis Reference
No information avaliable
GyneCure Molecular Weight
157.21 g/mol
GyneCure Melting Point
>300 oC
GyneCure H2O Solubility
1.67E+005 mg/L
GyneCure State
Solid
GyneCure LogP
0.66
GyneCure Dosage Forms
Tablets containing 500 mg of tranexamic acid; Sterile solution for intravenous injection containing 100 mg tranexamic acid
GyneCure Indication
For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
GyneCure Pharmacology
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
GyneCure Absorption
Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.
GyneCure side effects and Toxicity
Oral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.
GyneCure Patient Information
GyneCure Organisms Affected
Humans and other mammals
